

Crompton

RECEIVED
OPPT CBIC

8EHQ-0902-15201

Product Safety and Regulatory Affairs

2002 SEP 24 AM 6:18

62219

September 13, 2002

Document Processing Center (TS-790)
Office of Toxic Substances
US Environmental Protection Agency
401 M Street SW
Washington, DC 20460

Attn: TSCA 8(e) Coordinator

COMPANY SANITIZED

Dear Sir or Madam:

Please find enclosed confidential and non-confidential copies of a Section 8(e) submission relevant to testing we have performed on one of our products. Please hold the trade name and indicated compositional information confidential.

Sincerely,



Alan Taylor, Ph.D.
Director Product Safety and Regulatory Affairs
Crompton Corporation

8EHQ-02-15201

65020000127



Responsible Care®
A Public Commitment



Fax: (304) 652-1478

[illegible]

The information provided in this letter is based on the instructions regarding reportability of toxicity data stated in the EPA's TSCA Section 8(e) Reporting Guide. This information was received as described herein on September 3, 2002. This information is summarized below.

A study of ***** in Sprague-Dawley rats was conducted in order to evaluate the possible acute toxic effects of ***** when administered once orally (gavage) to rats. The oral route was selected since this is an acceptable and standard method for administering the test article under OECD Guideline 407. Ingestion is not a potential route of exposure for humans, other than through accidental ingestion by workers handling the test article.

Treatment was by oral gavage with the neat test substance. The calculated LD₅₀ for ***** was greater than 2000 mg/kg of body weight. There were no mortalities. Clinical signs were observed and included impaired muscle coordination in all animals on day 0 and persisted in all males on day 1, but had subsided by day 2. Prostration was observed in three males on day 0 and in one male on day 2. Hypoactivity was observed in four males and one female on day 0 and in one male on day 1. Other signs included various discolored areas due to discharges/excretions, increased respiration rate (one animal), labored respiration and partial closure of the eye(s) (one animal). All animals appeared normal by day 4.

Please contact the undersigned with questions, if any, at (203) 573-2219.

Sincerely,

A handwritten signature in black ink, appearing to read "Alan Taylor", with a stylized flourish extending from the end.

Alan Taylor, Ph.D.
Director, Product Safety and Regulatory Affairs
Crompton Corporation